Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-–C) reduction beyond six years of treatment1 Eight in ten patients achieved target LDL-C threshold**, in line with…
Comments Off on Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years